BridgeBio Pharma, Inc. (BBIO)

BridgeBio Pharma, Inc. (BBIO) Healthcare & Pipeline Overview

BridgeBio Pharma, Inc. is a biotechnology company dedicated to the discovery, development, and delivery of innovative medicines for genetic diseases. With a diverse pipeline of 30 programs, including late-stage assets for conditions like ATTR-CM and achondroplasia, the company aims to address significant unmet medical needs through specialized therapeutic solutions and strategic collaborations.

What Is the Investment Thesis for BBIO?

BridgeBio Pharma, Inc. presents a research-driven profile within the biotechnology sector, characterized by an extensive and diversified pipeline of 30 development programs targeting various genetic diseases. A key value driver is the advancement of late-stage assets, notably AG10 and BBP-265, which are in Phase 3 clinical trials for ATTR-CM, representing a significant market opportunity upon potential approval. The company's high gross margin of 93.8% indicates strong potential profitability on any future product sales, although its current profit margin of -125.2% reflects the substantial R&D investments typical of a development-stage biotech. Growth catalysts include successful progression and positive data readouts from its numerous clinical trials, particularly those in Phase 2 and 3, which could de-risk assets and pave the way for regulatory submissions. The company's focus on genetic diseases, often with unmet needs, provides a specialized market niche. With a market capitalization of $15.51B and a Beta of 1.02, BBIO exhibits market-like volatility, aligning with the inherent risks and potential rewards of a biotechnology company with a deep pipeline.

Based on FMP financials and quantitative analysis

BBIO Key Highlights

• BridgeBio Pharma, Inc. maintains an extensive pipeline of 30 development programs, spanning from early discovery to late-stage clinical trials, demonstrating a broad approach to genetic disease therapeutics.
• The company's gross margin stands at 93.8%, indicating strong potential profitability on product sales, contrasting with its current negative profit margin of -125.2% due to significant R&D expenditures.
• Key late-stage assets include AG10 and BBP-265, which are currently in Phase 3 clinical trials for the treatment of TTR amyloidosis-cardiomyopathy (ATTR-CM), representing a substantial market opportunity.
• BridgeBio operates with a market capitalization of $15.51B, positioning it as a significant player within the specialized biotechnology sector focused on genetic diseases.
• The company employs 725 individuals, reflecting the substantial human capital investment required to manage its extensive research, development, and clinical operations.

Who Are BBIO's Competitors?

BBIO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BBIO's Key Strengths?

• Extensive pipeline of 30 development programs targeting a wide range of genetic diseases, providing multiple shots on goal.
• Advanced late-stage assets, including AG10 and BBP-265 in Phase 3 for ATTR-CM, indicating potential near-term commercialization.
• High gross margin of 93.8%, suggesting strong profitability potential upon product approval and sales.
• Strategic collaborations with prestigious academic institutions and research organizations, enhancing research capabilities and intellectual property.
• Focus on diseases with high unmet medical needs, potentially leading to premium pricing and orphan drug designations.

What Are BBIO's Weaknesses?

• Significant negative profit margin of -125.2%, reflecting substantial R&D expenditures typical of a development-stage biotech with no commercialized products.
• Reliance on successful clinical trial outcomes, which are inherently uncertain and can lead to significant delays or failures.
• High cash burn associated with extensive research and development activities across 30 programs.
• Lack of currently commercialized products means no recurring revenue streams from sales.
• The complexity of genetic diseases and gene therapies presents significant scientific and clinical challenges.

What Could Drive BBIO Stock Higher?

• Anticipated data readouts from the Phase 3 clinical trial for AG10 and BBP-265 in TTR amyloidosis-cardiomyopathy (ATTR-CM), which could lead to regulatory filings.
• Progression of BBP-831 through Phase 2 clinical trials for achondroplasia in pediatric patients, with potential for further advancement based on efficacy and safety data.
• Results from the Phase 2 clinical trial of BBP-631, an AAV5 gene transfer product candidate, for congenital adrenal hyperplasia (CAH) driven by 21OHD.
• Outcomes from the Phase 2 proof-of-concept clinical trial for Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1), which could validate its mechanism of action.
• Continued advancement of the remaining 25+ development programs across various stages, with potential for new clinical trial initiations or data presentations.

What Are the Key Risks for BBIO?

• Financial-distress signal — its Altman Z-Score of -2.32 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Rich valuation — a P/E of 355.7 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
• Significant financial losses reflected by a -125.2% profit margin, driven by high research and development expenses inherent in a clinical-stage biotechnology company.
• Clinical trial failures or unexpected adverse events for any of the 30 pipeline programs, which could result in substantial delays, increased costs, or complete discontinuation of development.
• Regulatory hurdles and prolonged review periods by health authorities, which could delay or prevent the approval of BridgeBio's drug candidates, impacting commercialization timelines.
• Intense competition within the biotechnology sector, particularly in the genetic disease space, from both established pharmaceutical companies and other emerging biotechs.
• Dependence on successful execution of license and collaboration agreements, as any issues with these partnerships could impact development progress or access to key technologies.

What Are the Growth Opportunities for BBIO?

• Growth opportunity 1: Successful commercialization of AG10 and BBP-265 for ATTR-CM. These small molecule TTR stabilizers are currently in Phase 3 clinical trials, representing a significant near-term opportunity. Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is a progressive and fatal disease with a substantial patient population and high unmet medical need. Positive outcomes from the ongoing Phase 3 trials and subsequent regulatory approval could unlock a multi-billion dollar market, establishing BridgeBio as a key player in cardiovascular rare diseases. The market for ATTR-CM therapies is expanding, and a differentiated oral small molecule could capture significant share.
• Growth opportunity 2: Advancement and approval of BBP-831 for achondroplasia. This selective FGFR1-3 inhibitor is in Phase 2 clinical trials for pediatric patients with achondroplasia, the most common form of dwarfism. Currently, treatment options are limited, and a therapy that can address the underlying genetic cause holds immense potential. The global market for achondroplasia treatments is projected to grow, driven by increasing diagnosis and demand for effective therapies. Successful development and commercialization of BBP-831 would position BridgeBio to address a critical need in pediatric rare diseases, offering a significant revenue stream and market leadership.
• Growth opportunity 3: Clinical success and market entry for BBP-631 in congenital adrenal hyperplasia (CAH). BBP-631, an AAV5 gene transfer product candidate, is in Phase 2 clinical trials for CAH driven by 21-hydroxylase deficiency (21OHD). CAH is a severe genetic disorder requiring lifelong steroid replacement therapy, which comes with significant side effects. A gene therapy approach could offer a transformative, potentially curative, treatment. The rare disease nature of CAH, combined with the innovative gene therapy modality, suggests a high-value market opportunity if BBP-631 demonstrates efficacy and safety, allowing BridgeBio to enter the nascent but rapidly growing gene therapy market.
• Growth opportunity 4: Development and approval of Encaleret for Autosomal Dominant Hypocalcemia Type 1 (ADH1). Encaleret, a small molecule antagonist of the calcium sensing receptor (CaSR), is in a Phase 2 proof-of-concept clinical trial for ADH1. ADH1 is a rare genetic disorder characterized by low calcium levels due to overactive CaSR, for which current treatments are often inadequate. A targeted therapy like Encaleret could significantly improve patient outcomes and quality of life. The orphan drug designation potential and the specific mechanism of action position BridgeBio to address a niche but high-value market, demonstrating its capability in precision medicine for rare endocrine disorders.
• Growth opportunity 5: Expansion into hyperoxaluria and recurrent kidney stone treatment with BBP-711. This product candidate targets hyperoxaluria, a condition characterized by excessive oxalate in the urine, leading to recurrent kidney stones and potential kidney damage. While in earlier stages of development, BBP-711 addresses a widespread and chronic health issue. The market for kidney stone prevention and treatment is substantial, and a novel therapeutic approach for hyperoxaluria could capture a significant share, particularly for patients with severe or recurrent conditions. This represents an opportunity for BridgeBio to diversify its pipeline beyond ultra-rare diseases into broader, yet still specialized, therapeutic areas.

What Opportunities Does BBIO Have?

• Successful completion of Phase 3 clinical trials for AG10/BBP-265, leading to regulatory approval and market entry for ATTR-CM.
• Positive data readouts from Phase 2 trials for BBP-831 (achondroplasia), BBP-631 (CAH), Encaleret (ADH1), and BBP-711 (hyperoxaluria), advancing these candidates towards pivotal studies.
• Expansion into new therapeutic areas or indications within genetic diseases through ongoing discovery efforts and pipeline diversification.
• Potential for strategic partnerships or licensing agreements for pipeline assets, providing non-dilutive funding and broader market access.
• Leveraging advancements in gene therapy and precision medicine to develop first-in-class or best-in-class treatments for severe genetic conditions.

What Threats Does BBIO Face?

• Clinical trial failures or unexpected safety concerns for any of its 30 development programs, leading to significant setbacks and financial losses.
• Intense competition from other biotechnology and pharmaceutical companies developing similar or alternative therapies for genetic diseases.
• Regulatory hurdles and delays in obtaining approvals from health authorities, impacting commercialization timelines.
• Patent expirations or challenges to intellectual property, potentially leading to generic or biosimilar competition in the future.
• Changes in healthcare policy, reimbursement landscapes, or economic conditions that could impact drug pricing and market access.

What Are BBIO's Competitive Advantages?

• Extensive and diversified pipeline of 30 development programs targeting various genetic diseases, reducing reliance on a single asset's success.
• Focus on genetic diseases, often associated with orphan drug designations and specialized regulatory pathways, potentially leading to market exclusivity.
• Strategic collaborations with leading academic institutions (e.g., Stanford, UC Regents) and research organizations, enhancing R&D capabilities and intellectual property.
• Expertise in multiple therapeutic modalities, including small molecules and gene therapies, allowing for tailored approaches to complex genetic conditions.
• Advancement of several candidates into late-stage clinical trials (e.g., Phase 3 for ATTR-CM), indicating significant progress and potential for market entry.

What Does BBIO Do?

BridgeBio Pharma, Inc., founded in 2015 and headquartered in Palo Alto, California, is a clinical-stage biotechnology company committed to identifying, developing, and delivering transformative medicines for patients suffering from genetic diseases. The company's operational model is centered around a diverse and extensive pipeline, currently encompassing 30 development programs that range across all stages from early discovery research to pivotal late-stage clinical trials. This broad portfolio reflects a strategic approach to tackling a wide spectrum of genetic conditions, including Mendelian, oncology, and gene therapy diseases. Key product candidates within BridgeBio's pipeline include AG10 and BBP-265, which are small molecule stabilizers of transthyretin (TTR) currently in Phase 3 clinical trials for the treatment of TTR amyloidosis-cardiomyopathy (ATTR-CM), a serious and progressive condition. Another significant program is BBP-831, a small molecule selective FGFR1-3 inhibitor, undergoing Phase 2 clinical trials for achondroplasia in pediatric patients. Additionally, BBP-631, an AAV5 gene transfer product candidate, is in Phase 2 clinical trials for congenital adrenal hyperplasia (CAH) driven by 21-hydroxylase deficiency (21OHD). The company is also advancing Encaleret, a small molecule antagonist of the calcium sensing receptor (CaSR), in a Phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-711 for hyperoxaluria and recurrent kidney stones. BridgeBio Pharma leverages strategic license and collaboration agreements with prominent academic institutions such as The Leland Stanford Junior University, The Regents of the University of California, and research organizations like Leidos Biomedical Research, Inc., to bolster its research and development capabilities and accelerate its mission to bring new therapies to patients.

What Products and Services Does BBIO Offer?

• Discovers and develops new medicines specifically for genetic diseases.
• Maintains a broad pipeline of 30 drug development programs, from early research to late-stage clinical trials.
• Focuses on conditions such as TTR amyloidosis-cardiomyopathy (ATTR-CM) with Phase 3 candidates.
• Develops treatments for pediatric genetic disorders like achondroplasia (Phase 2).
• Advances gene therapy candidates, including BBP-631 for congenital adrenal hyperplasia (CAH).
• Explores therapies for metabolic and endocrine rare diseases like Autosomal Dominant Hypocalcemia Type 1 (ADH1).
• Engages in strategic licensing and collaboration agreements with academic institutions and research organizations.
• Aims to deliver medicines for Mendelian, oncology, and gene therapy diseases.

How Does BBIO Make Money?

• Primarily generates revenue through the discovery, development, and potential future commercialization of proprietary drug candidates for genetic diseases.
• Involves significant investment in research and development (R&D) to advance its pipeline through preclinical and clinical trial phases.
• Relies on successful clinical trial outcomes and subsequent regulatory approvals to bring products to market.
• Leverages licensing and collaboration agreements to access intellectual property, share development costs, and potentially receive milestone payments or royalties.
• Future revenue streams are expected from direct product sales upon successful commercialization of approved therapies.

What Industry Does BBIO Operate In?

BridgeBio Pharma, Inc. operates within the highly specialized and innovation-driven Biotechnology industry, a sub-sector of Healthcare. This industry is characterized by intensive research and development efforts aimed at discovering, developing, and commercializing novel therapeutic solutions, particularly for diseases with high unmet medical needs. BridgeBio's specific focus on genetic diseases positions it within a segment that often involves orphan drug designations and accelerated regulatory pathways, potentially leading to premium pricing and market exclusivity upon approval. The broader biotechnology market is experiencing significant growth driven by advancements in genomics, gene therapy, and precision medicine. Competitively, BridgeBio faces established pharmaceutical companies and other emerging biotechs. Its strategy of maintaining a diverse pipeline of 30 programs across various stages and therapeutic areas, from Mendelian to oncology and gene therapy, allows it to mitigate some of the inherent risks associated with drug development by not relying on a single asset. This approach places BridgeBio as a multifaceted developer in the genetic disease space, competing for research talent, intellectual property, and market share against peers like Revolution Medicines, Inc., Roivant Sciences Ltd., and Moderna, Inc.

Who Are BBIO's Key Customers?

• Patients suffering from a wide range of genetic diseases, including rare and ultra-rare conditions like ATTR-CM, achondroplasia, CAH, and ADH1.
• Healthcare providers, including specialists in cardiology, endocrinology, genetics, and nephrology, who treat patients with these specific genetic disorders.
• Potentially, pharmaceutical partners through licensing or co-development agreements for specific pipeline assets.
• Global healthcare systems and payers, who will ultimately cover the costs of approved therapies.

Company Profile

BridgeBio Pharma, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Palo Alto, US. The company is led by CEO Neil Kumar. BBIO has traded publicly since 2019.

ROE 36%Key Financial Metrics

Return on equity for BridgeBio Pharma, Inc. stands at 36.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -52.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -3.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.44 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -5.5%, the inverse of the P/E and a quick read on earnings relative to price.

BBIO Valuation & Market Position

With a $15.51B market cap, BridgeBio Pharma, Inc. sits in the large-cap segment of the market. Relative to its peer group, BBIO's quantitative score of 10/100 is below the peer average of 51/100.

Quarterly Financial Performance: BridgeBio Pharma, Inc.

Revenue for BridgeBio Pharma, Inc. came in at $194.5M during Q1 2026, a 26.2% improvement versus the preceding quarter. The company recorded a net loss of $164.0M, with diluted EPS of $-0.84. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this large-cap Healthcare company. Across the four most recent quarters, BBIO averaged $-0.94 in diluted EPS.

F-Score 2/9Financial Health

BridgeBio Pharma, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -2.32 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project BridgeBio Pharma, Inc. revenue of about $968.9M for fiscal 2026, with EPS near $-2.17. The estimate reflects 17 contributing analysts.

Net buyingInsider Activity

Over the past six months, BridgeBio Pharma, Inc. insiders filed 30 SEC Form 4 transactions — 7 sales and 23 purchases. On net that is roughly 48K shares acquired (about $543K) — insiders putting money in tends to read as conviction.

BBIO Financials

BBIO Latest News

BBIO Analyst Consensus

BBIO MoonshotScore

Latest BridgeBio Pharma, Inc. Analysis

Common Questions About BBIO (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources